EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Experience with sotrovimab treatment of SARS‐CoV‐2‐infected patients in Denmark

Line Dahlerup Rasmussen iD, Anne-Mette Lebech, Anne Øvrehus, Birgitte Klindt Poulsen, Hanne Rolighed Christensen, Henrik Nielsen, Isik Somuncu Johansen, Lars Haukali Omland, Lothar Wiese, Marie Helleberg, Merete Storgaard, Michael Dalager-Pedersen und 8 weitere

British Journal of Clinical Pharmacology · 2023

DOI: 10.1111/bcp.15644 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2023. Verfasst von Line Dahlerup Rasmussen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease, Odense University Hospital, Odense C, Denmark & Research Unit for Infectious Diseases, University of Southern Denma…. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the experience with use of sotrovimab following severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection in high‐risk groups.

Methods

In a nationwide, population‐based cohort study, we identified all individuals treated with sotrovimab ( N = 2933) and stratified them by 4 high‐risk groups: (A) malignant haematological disease, (B) solid organ transplantation, (C) anti‐CD20 therapy ≤1 year and (D) other risks. Cox regression analysis was used to calculate hazard ratios for hospitalization, death and associated prognostic factors.

Results

Of 2933 sotrovimab‐treated individuals, 83% belonged to high‐risk groups (37.6% haematological malignancy, 27.4% solid organ transplantation and 17.5% treatment with anti‐CD20 ≤1 year). Only 17.8% had other risks (11.8% were pregnant, 10.7% primary immunodeficiency, 21.2% other malignancy, 4.3% received anti‐CD20 >1 year and 52.0% other/unknown causes). Within 90 days of infusion, 30.2% were hospitalized and 5.3% died. The main prognostic factors were the predefined high‐risk groups, mainly malignant haematological disease and age ≥65 years. Number of COVID‐19 vaccines (≥3) was associated with a decreased risk of hospitalization. The Delta but not the Omicron BA.2 variant was associated with a higher risk of death compared to the BA.1 variant.

Conclusion

More than 90% of the patients treated with sotrovimab belonged to the very high‐risk groups as described in the Danish guidelines. Sotrovimab‐treated individuals remained at a high risk of hospitalization and death which was strongly associated with the underlying immunocompromised state and age. Having received >3 COVID‐19 vaccines was association with decreased risk of death and hospitalization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19FemalePregnancyHumansAgedCOVID-19 VaccinesCohort StudiesDenmarkAntibodies, NeutralizingAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

COVID-19SARS-CoV-2SARS-CoV-2 vaccinesmABsotrovimab

Substanzen

COVID-19 VaccinessotrovimabAntibodies, NeutralizingAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Infectious Disease, Odense University Hospital, Odense C, Denmark & Research Unit for Infectious Diseases, University of Southern Denmark, Odense, Denmark.
  • Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Clinical Pharmacology, Aalborg University Hospital, Aalborg, Denmark.
  • Department of Clinical Pharmacology, Copenhagen University Hospital, Copenhagen, Denmark.
  • Department of Infectious Diseases, Aalborg University Hospital, Aalborg, Denmark.

ORCID-Profile: Line Dahlerup Rasmussen

Zitieren

APA

Rasmussen, L. D., Lebech, A. M., Øvrehus, A., Poulsen, B. K., Christensen, H. R., Nielsen, H., Johansen, I. S., Omland, L. H., Wiese, L., Helleberg, M., Storgaard, M., Dalager-Pedersen, M., Rasmussen, T. A., Benfield, T., Petersen, T. S., Andersen, Å. B., Gram, M. A., Stegger, M., Edslev, S. M., & Obel, N. (2023). Experience with sotrovimab treatment of SARS‐CoV‐2‐infected patients in Denmark. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15644

Vancouver

Rasmussen LD, Lebech AM, Øvrehus A, Poulsen BK, Christensen HR, Nielsen H, et al. Experience with sotrovimab treatment of SARS‐CoV‐2‐infected patients in Denmark. British Journal of Clinical Pharmacology. 2023. doi:10.1111/bcp.15644

BibTeX
@article{Rasmussen2023,
  author = {Rasmussen, Line Dahlerup and Lebech, Anne-Mette and Øvrehus, Anne and Poulsen, Birgitte Klindt and Christensen, Hanne Rolighed and Nielsen, Henrik and Johansen, Isik Somuncu and Omland, Lars Haukali and Wiese, Lothar and Helleberg, Marie and Storgaard, Merete and Dalager-Pedersen, Michael and Rasmussen, Thomas A and Benfield, Thomas and Petersen, Tonny Studsgaard and Andersen, Åse Bengård and Gram, Mie Agermose and Stegger, Marc and Edslev, Sofie Marie and Obel, Niels},
  title = {Experience with sotrovimab treatment of SARS‐CoV‐2‐infected patients in Denmark},
  journal = {British Journal of Clinical Pharmacology},
  year = {2023},
  doi = {10.1111/bcp.15644}
}
Kostenlos starten →